Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L13a pseudogene 6 (RPL13AP6) is a human pseudogene related to the functional ribosomal protein L13a gene. Pseudogenes are segments of DNA that closely resemble functional genes but lack the ability to encode functional proteins, often due to mutations or lack of regulatory elements. RPL13AP6 does not encode a functional protein and is presumed to have no direct biological or therapeutic target function. It is classified as one of multiple processed pseudogenes distributed in the human genome for the ribosomal protein L13a gene. There are no known functions, disease associations, or pharmacological interactions attributed to this pseudogene[2][3][8][10][11][14]. Key notes: - RPL13AP6 should not be confused with RPL13A, which is a protein-coding gene with well-characterized roles in ribosome assembly and immune regulation[1][4][7]. - As a pseudogene, RPL13AP6 is rarely, if ever, referenced as a therapeutic target, receptor, enzyme, or involved in molecular pharmacology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L13a pseudogene 6 (RPL13AP6).